Mobile

A 4-week, parallel-group, randomized, double-blind, placebo-controlled, adaptive proof of concept study of AQW051 at up to three dose levels for the treatment of patients with findings consistent with...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-001846-42

A 4-week, parallel-group, randomized, double-blind, placebo-controlled, adaptive proof of concept study of AQW051 at up to three dose levels for the treatment of patients with findings consistent with mild Alzheimer’s disease (AD) or Mild Cognitive Impairment (amnestic MCI)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess AQW051 as a cognitive enhancer, as measured by selected tests (PAL, SWM, RVP) from the CANTAB computerized cognitive test battery, in patients with findings consistent with mild Alzheimer’s disease (AD) or amnestic mild cognitive impairment (amnestic MCI).

Critère d'inclusion

  • Mild Alzheimer’s disease (AD) and amnestic mild cognitive impairment (amnestic MCI)

Liens